Compare BBIO & BSAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBIO | BSAC |
|---|---|---|
| Founded | 2015 | 1977 |
| Country | United States | Chile |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7B | 13.7B |
| IPO Year | 2019 | 1994 |
| Metric | BBIO | BSAC |
|---|---|---|
| Price | $74.32 | $32.30 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 21 | 2 |
| Target Price | ★ $78.43 | $29.50 |
| AVG Volume (30 Days) | ★ 1.9M | 244.9K |
| Earning Date | 02-19-2026 | 02-06-2026 |
| Dividend Yield | N/A | ★ 3.06% |
| EPS Growth | N/A | ★ 42.15 |
| EPS | N/A | ★ 0.01 |
| Revenue | $353,780,000.00 | ★ $2,434,135,287.00 |
| Revenue This Year | $127.64 | $41.02 |
| Revenue Next Year | $78.38 | $6.06 |
| P/E Ratio | ★ N/A | $13.72 |
| Revenue Growth | ★ 62.46 | 20.98 |
| 52 Week Low | $28.10 | $18.19 |
| 52 Week High | $78.59 | $33.49 |
| Indicator | BBIO | BSAC |
|---|---|---|
| Relative Strength Index (RSI) | 51.53 | 66.63 |
| Support Level | $71.19 | $31.03 |
| Resistance Level | $75.57 | $33.49 |
| Average True Range (ATR) | 2.44 | 0.58 |
| MACD | -0.65 | 0.10 |
| Stochastic Oscillator | 38.54 | 68.36 |
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Founded in 1978, Banco Santander Chile is part of Santander Group and majority-controlled by Santander Spain. It is the largest bank in Chile by loans and the second largest by deposits. The bank generates most of its net interest income (roughly 65% of total revenue) from its mortgages, unsecured consumer credit lines, and commercial loans. Banco Santander's commercial loan business is more focused on small- to medium-size companies, with firms generating more than CLP 10,000 million in revenue only making up around 5% of outstanding loans. Outside of lending, Banco Santander is the largest card issuer in the country with around 25% of the market and benefits from a long-term strategic partnership with the largest airline in the country, LATAM.